Purpose Irinotecan (CPT-11) is widely used for the treatment of patients with colorectal cancer. However, the adverse effects associated with the treatment have hindered the efficacies of irinotecan. We have shown that organic selenium compounds could significantly attenuate irinotecan-associated toxicity and enhance antitumor activity in xenograft tumor models. The objective of this study is to determine the role of a specific group of uridine diphosphate glucuronosyltransferases, which is coded by UGT1A, in detoxification process of irinotecan as well as seleniumassociated protective effect against irinotecan-induced toxicity. Methods In this study, the toxicities of irinotecan, docetaxel and cisplatin in the Ugta1 mutant rats and their wildtype controls were compared. The plasma concentrations of irinotecan and SN-38 were measured. The modulatory effect of a selenium compound on irinotecan-induced toxicity was analyzed in these rats.
Introduction
As a chemotherapeutic agent, irinotecan is used extensively in the treatment for cancers, particularly colorectal cancer [1] . Irinotecan is converted by carboxylesterases to its active metabolite, SN-38, which can stabilize ternary complexes between topoisomerase I and DNA and thereby cause replication fork arrest and double-stranded DNA breaks [2] [3] [4] [5] [6] . In combination therapy, irinotecan together with 5-fluorouracil and leucovorin can lead to positive responses in about half the patients with advanced colorectal cancer, but 20-30% of these patients develop severe adverse responses, such as diarrhea and neutropenia [7, 8] . This dose-limiting toxicity may affect the therapeutic potential of irinotecan in cancer treatment. SN-38 is the active metabolite of irinotecan responsible for its toxicity and antitumor activity [9] [10] [11] . Irinotecan is detoxified in part by converting SN-38 to SN-38G through glucuronidation catalyzed by a specific group of uridine diphosphate glucuronosyltransferases (UDPGT) in the liver and intestines, which is coded by UGT1A [12, 13] . A portion of irinotecan is degraded in vivo to APC, NPC, M1, 2, 3, 4, catalyzed by CYP3A4 and CYP3A5, which are far less toxic than SN-38 [1, 14] . We have been exploring approaches to enhancing the therapeutic selectivity of irinotecan by focusing on the selenium-containing compounds. Selenium is an essential trace element, and dietary selenium is predominantly in the form of organic compounds, such as 5-methylselenocysteine (MSC), a known antioxidant. It was confirmed that therapeutic doses of selenium effectively protect against irinotecan-induced toxicity in rodent models with the wild-type Ugt1a allele [15, 16] . Our results showed that MSC administrated prior and concurrently with irinotecan could significantly reduce the toxic effects of irinotecan, allowing the administration of higher dosages, which resulted in improved therapeutic efficacies and cures in tumor xenograft models with the wild-type Ugt1a allele [15, 16] . In contrast, using Ugt1a mutant rats, MSC did not offer any significant protection from irinotecan-induced toxicity. These data provide further evidence for the role of Ugt1a in the detoxification of irinotecan.
Results and discussion
In this study, we set out to study the factors associated with the toxicity and detoxification of irinotecan by comparing Ugta1 mutant rats and the wild-type controls. We first wanted to confirm the role of the rat ortholog of UGT1A, Ugt1a, in irinotecan detoxification by comparing the toxic effects of irinotecan on homozygous Gunn rats (j/j), heterozygous Gunn rats (j/?) and wild-type controls. The Gunn rats carry a frameshift mutation, which causes a complete loss of the enzymatic activities of UDPGT coded by the Ugt1a locus [17] [18] [19] . In the experiments, we used 8-to-12-week-old female j/j and j/? rats and their wild- for the different groups of the rats, which was defined as the maximum dose that could be administered to animals, which resulted in no drug-related lethality and body weight loss of less than 20%. After drug administration, the rats were monitored daily for drug-induced toxic effects, including body weight loss, diarrhea, stomatitis and lethality, for a minimum of 2 weeks, and 3-4 times a week thereafter. The differences between the mean values in the different treatment groups were analyzed for significance using one-way analysis of variances (ANOVA), with Tukey-Kramer multiple comparison tests. A P value of less than 0.05 was considered statistically significant. The analysis of our experimental data showed that, following a single i.v. injection of irinotecan, the MTD were 200 mg/kg and 25 mg/kg for ?/? and j/j rats, respectively. Using the daily 9 3 schedule, the MTD were 100 mg/kg Tables S1  and S3 ). Our results showed that severe diarrhea is a dosage-limiting condition associated with lethality in the treated rats (Table 1 ; Online Resource Table S3 ). The plasma concentrations of irinotecan and SN-38 were measured 1 h after the administration of irinotecan to j/j and ?/? rats using a validated high-performance liquid chromatography method, as previously described [20] . The separation method was carried out on a Waters Nova-Pak C18 column equipped with a l Bondapak C18 guard column, with the mobile phase consisting of 20% acetonitrile and 80% triethylamine acetate. Detection was by fluorescence with excitation at 370 nm and emission at 510 nm. The limit of quantitation for both was 2.5 ng/ml. Our results showed that the plasma concentrations of irinotecan and SN-38 in j/j rats were higher than those of the wildtype controls (Online Resource Table S2 ), which is consistent with the observations that mutations in the UGT1A locus caused the elevated levels of SN-38 in the patients treated with irinotecan [21] [22] [23] . The severity of the toxic response in j/? rats falls between that of j/j and ?/? rats (Table 1 ; Online Resource Fig. S4 and Table S3 ), reflecting the consequence of copy-number variations of the Ugt1a gene. These data confirm the critical role of Ugt1a in the detoxification of irinotecan. To determine the drug specificity for the role of the Ugt1a mutation in the detoxifications of irinotecan, we evaluated the toxic effects of different chemotherapeutic agents in rats with different genotypes. The results shown in Online Resource Fig. S5 and Table S4 indicated that the Ugt1a mutation did not adversely affect the MTD or toxic profiles of docetaxel and cisplatin, suggesting that toxicity and detoxification of irinotecan are specifically dependent on Ugt1a expression.
To examine the potential role of Ugt1a on the observed protection of selenium against irinotecan-associated toxicity in mice and rats with the wild-type Ugt1a [15, Cao et al. unpublished data], we evaluated the MTDs and toxic effects of irinotecan alone and in combination with MSC in Gunn rats. MSC was purchased from Sigma (St. Louis, MO, USA) and dissolved in sterile saline (0.9% NaCl) at a concentration of 1 mg/ml. MSC was administered orally (p.o.) once a day at 0.5 mg/rat/day, 7 days before and during and 7 days after irinotecan treatment. Our results indicate that, unlike the animals with the wild-type Ugt1a in which MSC offers strong protection against lethal doses of irinotecan and prevents irinotecan-induced diarrhea, bone marrow suppression and lethality [15, Cao et al. unpublished data] MSC did not yield any significant protection in j/j rats ( Fig. 1; Table 1 ). It is interesting to observe that MSC-associated protection was also evident for j/? rats (Online Resource Fig. S6 ; Table 1 ), suggesting MSC still played an essential role in alleviating the toxic effects of irinotecan, even when only one copy of Ugt1a was functional.
Besides being converted to SN-38 by carboxylesterases, irinotecan can also be metabolized to compounds that have fewer cytotoxic effects than SN-38, which is catalyzed by CYP3A4 and CYP3A5 in rats [1, 14, 24] . Thus, the protective effect of selenium against irinotecan-induced host toxicities could be due to the enhanced activities of carboxylesterases/UDPGT encoded by Ugt1a and/or Cyp3a4/ Cyp3a5 by selenium. Although it has been reported that selenium could significantly increase expression of Cyp3a5 [25] , it is presently unknown whether the expression of Cyp3a4 is elevated. Promoting expression of Ugt1a by selenium has also been reported [26, 27] . If seleniuminduced elevation of expression of Cyp3a4/Cyp3a5 plays a major role in the detoxification of irinotecan, the significant protection of selenium against irinotecan-associated toxicity should have remained even when Ugt1a is inactivated. Since our result showed that selenium-induced protection largely disappeared in Gunn rats, it suggests that the Cyp3a4/Cyp3a5-mediated metabolic pathway basically did not play a significant role in selenium-mediated protection. Therefore, we have established conclusively for the first time that Ugt1a is essential for selenium to exert its protective role against irinotecan-induced toxicity. Although it is possible that the selenium-induced elevated expression of Ugt1a may be a key reason, our results provide a strong impetus to fully explore the mechanistic details related to this phenomenon. Such an effort may lead to a better strategy in using selenium and/or novel modulators to increase the therapeutic efficacies of irinotecan in cancer treatment.
